---
figid: PMC3233287__onc0111109010002
figlink: /pmc/articles/PMC3233287/figure/F2/
number: F2
caption: 'Illustration of main mechanisms of trastuzumab resistance (in red) and targeted
  agents to circumvent resistance (in blue). Truncated HER-2 expression prevents binding
  of trastuzumab. Alternative signaling, such as through HER-3, can lead to continued
  downstream signaling. The PI3K–AKT pathway can be constitutively activated through
  loss of PTEN or PIK3CA mutations. Lapatinib inhibits downstream signaling of HER-2
  and p95HER-2. T-DM1 provides additional cytotoxic activity. HSP90 inhibitors, such
  as tanespimycin, lead to degradation of p95HER-2. Pertuzumab prevents dimerization
  of HER-2 and HER-3. Cixutumumab inhibits IGF-1R. Everolimus is a mTORC1 inhibitor.
  Other investigational agents in early clinical development are also shown in italics.Abbreviations:
  ERK, extracellular signal–related kinase; GRB2, growth factor receptor-bound protein
  2; HER-2, human epidermal growth factor receptor; HSP90, heat shock protein 90;
  IGF-1R, insulin-like growth factor 1 receptor; MEK, mitogen-activated protein kinase/ERK
  kinase; mTORC1, mammalian target of rapamycin complex 1; mTORC2, mammalian target
  of rapamycin complex 2; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol-bisphosphate;
  PIP3, phosphatidylinositol-trisphosphate; PTEN, phosphatase and tensin homologue
  deleted on chromosome ten; RHeB, Ras homolog enriched in brain; SOS; son of sevenless;
  T-DM1, trastuzumab–DM1 conjugate; TKI, tyrosine kinase inhibitor; TSC, tuberous
  sclerosis protein.'
pmcid: PMC3233287
papertitle: Integrating Molecular Mechanisms and Clinical Evidence in the Management
  of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer.
reftext: Hilda Wong, et al. Oncologist. 2011 Nov;16(11):1535-1546.
pmc_ranked_result_index: '109257'
pathway_score: 0.9809428
filename: onc0111109010002.jpg
figtitle: Illustration of main mechanisms of trastuzumab resistance (in red) and targeted
  agents to circumvent resistance (in blue)
year: '2011'
organisms:
- Homo sapiens
ndex: ceb4889d-debb-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3233287__onc0111109010002.html
  '@type': Dataset
  description: 'Illustration of main mechanisms of trastuzumab resistance (in red)
    and targeted agents to circumvent resistance (in blue). Truncated HER-2 expression
    prevents binding of trastuzumab. Alternative signaling, such as through HER-3,
    can lead to continued downstream signaling. The PI3K–AKT pathway can be constitutively
    activated through loss of PTEN or PIK3CA mutations. Lapatinib inhibits downstream
    signaling of HER-2 and p95HER-2. T-DM1 provides additional cytotoxic activity.
    HSP90 inhibitors, such as tanespimycin, lead to degradation of p95HER-2. Pertuzumab
    prevents dimerization of HER-2 and HER-3. Cixutumumab inhibits IGF-1R. Everolimus
    is a mTORC1 inhibitor. Other investigational agents in early clinical development
    are also shown in italics.Abbreviations: ERK, extracellular signal–related kinase;
    GRB2, growth factor receptor-bound protein 2; HER-2, human epidermal growth factor
    receptor; HSP90, heat shock protein 90; IGF-1R, insulin-like growth factor 1 receptor;
    MEK, mitogen-activated protein kinase/ERK kinase; mTORC1, mammalian target of
    rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; PI3K, phosphoinositide
    3-kinase; PIP2, phosphatidylinositol-bisphosphate; PIP3, phosphatidylinositol-trisphosphate;
    PTEN, phosphatase and tensin homologue deleted on chromosome ten; RHeB, Ras homolog
    enriched in brain; SOS; son of sevenless; T-DM1, trastuzumab–DM1 conjugate; TKI,
    tyrosine kinase inhibitor; TSC, tuberous sclerosis protein.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MLST8
  - MTOR
  - PIK3CG
  - TSC2
  - RICTOR
  - MAP2K2
  - AKT2
  - GRB2
  - RPTOR
  - AKT1
  - PIK3CD
  - IGF1R
  - SART3
  - AKT3
  - TSC1
  - MAPK1
  - MAPKAP1
  - PIK3R6
  - PIK3R3
  - HSP90B1
  - PIK3CA
  - MAP2K1
  - SOS2
  - SOS1
  - MAPK3
  - ERBB3
  - RAF1
  - PIK3R4
  - HRAS
  - PIK3CB
  - KRAS
  - TRAP1
  - HSP90AB1
  - PIK3R5
  - BRAF
  - NRAS
  - ARAF
  - PTEN
  - Neratinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: TSC2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: AKT/HSP90Lapatinib
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: GRB2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: MTORC1/2inhibitor
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: AKT/HSP90Lapatinib
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: IGF-1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: P110
  symbol: p110
  source: hgnc_alias_symbol
  hgnc_symbol: SART3
  entrez: '9733'
- word: MTORC1/2inhibitor
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: AKT/HSP90Lapatinib
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: TSC1
  symbol: TSC1
  source: hgnc_symbol
  hgnc_symbol: TSC1
  entrez: '7248'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: HSP90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: HSP90B1
  entrez: '7184'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: PIK3CA
  symbol: PIK3CA
  source: hgnc_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: HER-3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: HSP90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: TRAP1
  entrez: '10131'
- word: HSP90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: HSP90AB1
  entrez: '3326'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
chemicals:
- word: Neratinib
  source: MESH
  identifier: C487932
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC3233287__F2
redirect_from: /figures/PMC3233287__F2
figtype: Figure
---
